InvestorsHub Logo
Followers 10
Posts 605
Boards Moderated 0
Alias Born 06/30/2014

Re: None

Friday, 12/06/2019 2:02:25 AM

Friday, December 06, 2019 2:02:25 AM

Post# of 513
Failure of SAGE not good for anyone
Promising NMDAR drug, demonstrates the risk of holding thru test data release. Remind me to sell some RLMD at $300 in 2 years just before the phase 3 data is released

“So far everything I predicted has happened, not exactly when I said but within a reasonable timeframe:

1) raised $8mm,

2) executed the reverse split, to

3) get listed on NASDAQ, ( rang the bell at NASDAQ! didn't see that coming)

4) released excellent phase 2 data driving the stock from 11 to 36 that day.

5) Drifted down to 22, started up on unusual volume and trading indicative of large buyers,

6) announced and closed a 115MM - (including the 500,000 Green Shoe) secondary. I predicted '3mm shares at $50, someday' they did 3.8mm at $30 much earlier than I thought they could
Announced the deal and closed it the next day, deal 'oversubscribed' by 4 times! 10-15 mm shares of unmet demand drove it to $50 while everyone was bitching about 'dilution' Dilute me like that again please! Best outcome for current shareholders, allows RLMD to get closer to its real value with no takeover or unfavorable joint venture terms

Blue Horseshoe said Allergan, AXSM and Vistagen were BS, 3 out of the 4 leading MDD TRD competitors have failed, next one to fail is AXSM, doesn't compare to RLMD. Combination of a drug they don't own with cough medicine ?! WTF?!? and FDA doesn't like combination drugs.
PS: I beat Col. Sanders to $2mm NW by a few years. Now at $300/ share that’s $6mm more, not bad for a 55K investment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RLMD News